“We need all the capital we can get our hands on," the company states.

The company deprioritises its lead project, naporafenib, shifting to two Joyo-originated assets.

The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.

The young company’s eighth licensing deal brings in two RAS-targeting projects from Joyo.